Agility Clinical, Inc.

agility-clinical.com

Agility Clinical is a unique consulting and contract research organization dedicated to working with virtual, small biopharma and device companies with a lean infrastructure. We put our expertise and passion to work helping small companies - particularly those involved with orphan drug development - to move forward and bring important new treatments to patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SEXTON BIOTECHNOLOGIES PARTNERS WITH BIOSPHERIX TO CREATE A FULLY-ENCLOSED, MODULAR FILL-FINISH SYSTEM WITH RAPID DEPLOYMENT

Sexton Biotechnologies | June 11, 2020

news image

Sexton Biotechnologies has announced a new collaboration with BioSpherix Medical. As a tool and technologies partners of the Cell and Gene industry, Sexton and BioSpherix both recognize the need for cost-effective and flexible automation solutions during cell and gene therapy process development. While some upstream bioprocesses have been successfully automated, the final steps of downstream bioprocess, namely Fill-Finish, are often done manually with associated risks of contamination and user e...

Read More

Medical

CAJAL NEUROSCIENCE LAUNCHES WITH $96 MILLION TO TRANSFORM TARGET AND DRUG DISCOVERY IN NEURODEGENERATION

Cajal Neuroscience | November 30, 2022

news image

Cajal Neuroscience, a biotechnology company integrating human genetics, functional genomics and advanced microscopy to discover novel targets and therapeutics for neurodegeneration, launched today with the completion of a $96 million Series A financing. Cajal is uniquely focused on the mechanistic, spatial and temporal complexity of neurodegeneration, integrating deep expertise in neuroscience, neuroanatomy and computational biology with state-of-the-art technologies for high-throughput function...

Read More

Cell and Gene Therapy

NEW STUDY HIGHLIGHTS CELL AVIDITY'S POWER TO PROVIDE INSIGHTS INTO THE ROBUSTNESS OF T CELL ACTIVATION

LUMICKS | March 24, 2022

news image

LUMICKS, a next generation life science tools company, today announced that a research study published in Cellular and Molecular Life Sciences from the Radboud University Medical Center, led by researchers in the team of Professor G. J. Adema, detailed a novel method to study lead compound effects on immune cell interactions by employing LUMICKS' z-Movi® Cell Avidity Analyzer. The interaction between dendritic cells (DCs) and T cells is a critical step in the activation of...

Read More

Cell and Gene Therapy, Medical

OIAGEN STRENGTHENS HID WITH NGS TECHNOLOGIES BY ACQUIRING VEROGEN

QIAGEN | January 11, 2023

news image

QIAGEN recently announced its acquisition of Verogen, a leader in utilizing next-generation sequencing (NGS) technologies to advance the future of human identification (HID) and forensic investigation. QIAGEN, which introduced the first commercial kits to purify DNA from forensic casework samples in the late 1990s, is one of the leaders in the HID/forensics sector. Verogen, a privately-owned company launched in 2017, provides NGS tools and professional services to t...

Read More
news image

SEXTON BIOTECHNOLOGIES PARTNERS WITH BIOSPHERIX TO CREATE A FULLY-ENCLOSED, MODULAR FILL-FINISH SYSTEM WITH RAPID DEPLOYMENT

Sexton Biotechnologies | June 11, 2020

Sexton Biotechnologies has announced a new collaboration with BioSpherix Medical. As a tool and technologies partners of the Cell and Gene industry, Sexton and BioSpherix both recognize the need for cost-effective and flexible automation solutions during cell and gene therapy process development. While some upstream bioprocesses have been successfully automated, the final steps of downstream bioprocess, namely Fill-Finish, are often done manually with associated risks of contamination and user e...

Read More
news image

Medical

CAJAL NEUROSCIENCE LAUNCHES WITH $96 MILLION TO TRANSFORM TARGET AND DRUG DISCOVERY IN NEURODEGENERATION

Cajal Neuroscience | November 30, 2022

Cajal Neuroscience, a biotechnology company integrating human genetics, functional genomics and advanced microscopy to discover novel targets and therapeutics for neurodegeneration, launched today with the completion of a $96 million Series A financing. Cajal is uniquely focused on the mechanistic, spatial and temporal complexity of neurodegeneration, integrating deep expertise in neuroscience, neuroanatomy and computational biology with state-of-the-art technologies for high-throughput function...

Read More
news image

Cell and Gene Therapy

NEW STUDY HIGHLIGHTS CELL AVIDITY'S POWER TO PROVIDE INSIGHTS INTO THE ROBUSTNESS OF T CELL ACTIVATION

LUMICKS | March 24, 2022

LUMICKS, a next generation life science tools company, today announced that a research study published in Cellular and Molecular Life Sciences from the Radboud University Medical Center, led by researchers in the team of Professor G. J. Adema, detailed a novel method to study lead compound effects on immune cell interactions by employing LUMICKS' z-Movi® Cell Avidity Analyzer. The interaction between dendritic cells (DCs) and T cells is a critical step in the activation of...

Read More
news image

Cell and Gene Therapy, Medical

OIAGEN STRENGTHENS HID WITH NGS TECHNOLOGIES BY ACQUIRING VEROGEN

QIAGEN | January 11, 2023

QIAGEN recently announced its acquisition of Verogen, a leader in utilizing next-generation sequencing (NGS) technologies to advance the future of human identification (HID) and forensic investigation. QIAGEN, which introduced the first commercial kits to purify DNA from forensic casework samples in the late 1990s, is one of the leaders in the HID/forensics sector. Verogen, a privately-owned company launched in 2017, provides NGS tools and professional services to t...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us